Gilead Sciences, Inc. is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines in areas of unmet medical need. The company’s primary areas of focus include HIV, liver diseases, oncology, and inflammation and respiratory diseases. The company recently released its quarterly earnings report, which showed $1.67 earnings per share (EPS), beating the consensus estimate of $1.50 by $0.17. The business had revenue of $7.39 billion for the quarter, compared to analysts’ expectations of $6.63 billion. Gilead Sciences had a return on equity of 44.46% and a net margin of 16.83%. The firm’s quarterly revenue was up 2.0% on a year-over-year basis. The company has a market capitalization of $96.41 billion, a PE ratio of 21.18, and a beta of 0.38. Gilead Sciences increased its quarterly dividend to $0.75, up from $0.73, and has a dividend payout ratio of 82.19%. Insider trading has also occurred recently with Merdad Parsey selling 6,126 shares of the company’s stock in a transaction that occurred on Monday, March 13th.
FourThought Financial LLC Reduces Stake in Gilead Sciences by 15.5%
FourThought Financial LLC has reportedly lowered its stake in Gilead Sciences, Inc. by 15.5% during the third quarter, according to the company’s recent 13F filing. Other hedge funds and institutional investors have also made changes to their holdings in the company.
Recent Modifications to Holdings
JFS Wealth Advisors LLC has increased its stake in the biopharmaceutical company by 68.1%, owning 400 shares of the company’s stock valued at $25,000 after acquiring an additional 162 shares in the last quarter. Pacifica Partners Inc. and Horan Securities Inc. have increased their holdings by 179.7% and 217.9% respectively, and Capital Advisors Ltd. LLC has raised its holdings by 29.4%. Wagner Wealth Management LLC has also acquired a new position in Gilead Sciences.
Research Analyst Reports
Research analysts have issued reports on the company, with nine analysts rating the stock as “hold,” eight rating it as “buy,” and one giving it a strong buy rating. SVB Leerink boosted the company’s price target from $81.00 to $91.00 and gave it a “market perform” rating. Barclays upped its target price from $76.00 to $84.00 and gave the stock an “equal weight” rating, while Bank of America reiterated a “neutral” rating and set a target price of $85.00 on shares of Gilead Sciences. Morgan Stanley also increased its target price from $80.00 to $81.00, and Royal Bank of Canada reduced its target price from $87.00 to $86.00, giving the stock a “sector perform” rating.
Gilead Sciences Stock Performance
According to data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $89.40.
Gilead Sciences Stock Information
Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) opened at $77.31 on Friday, with a market capitalization of $96.41 billion. The stock has a PE ratio of 21.18, a price-to-earnings-growth ratio of 0.95, and a beta of 0.38. The company has a 12-month low of $57.17 and a 12-month high of $89.74. The stock’s 50-day simple moving average is $83.20, and its 200-day simple moving average is $78.51.
Quarterly Earnings Report
Gilead Sciences reported quarterly earnings on Thursday, February 2nd, announcing earnings per share (EPS) of $1.67, beating the consensus estimate of $1.50 by $0.17. The company had revenue of $7.39 billion for the quarter, compared to analysts’ expectations of $6.63 billion. Gilead Sciences had a return on equity of 44.46% and a net margin of 16.83%. The firm’s quarterly revenue was up 2.0% year-over-year. For the current fiscal year, research analysts forecast that Gilead Sciences, Inc. will post 6.84 earnings per share.
Dividend Increase
Gilead Sciences recently declared a quarterly dividend of $0.75 per share, to be paid on Thursday, March 30th. Investors of record on Wednesday, March 15th, will receive the dividend, which is an increase from the previous quarterly dividend of $0.73. The ex-dividend date of this dividend is Tuesday, March 14th. The annualized dividend is $3.00, with a yield of 3.88%. Gilead Sciences’s dividend payout ratio is 82.19%.
Insider Selling Activity
In other news, insider Merdad Parsey sold 6,126 shares of the company’s stock on Monday, March 13th, at an average price of $78.99, for a total value of $483,892.74. Following the transaction, the insider now directly owns 70,130 shares of the company’s stock, valued at approximately $5,539,568.70. This was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. As of now, 0.16% of the stock is currently owned by insiders.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines in areas of unmet medical need. The company’s primary areas of focus include HIV, liver diseases, oncology, and inflammation and respiratory diseases.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines in areas of unmet medical need. The company’s primary areas of focus include HIV, liver diseases, oncology, and inflammation and respiratory diseases.
Recommended Stories
Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating). Receive a concise daily summary of the latest news and analysts’ ratings for Gilead Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.
Don’t miss interesting posts on Famousbio
